What Nordic Pharma does

Nordic Pharma, Inc. is the U.S. commercial arm of Nordic Group, a privately owned pan-European pharmaceutical company headquartered in Paris and founded in 1995. The U.S. entity is built around a single commercialized product, LACRIFILL Canalicular Gel, an FDA-cleared interventional therapy for dry eye disease that works by temporarily blocking tear drainage via a proprietary gel formulation delivered through prefilled syringes. The product received FDA clearance in May 2024 and was enhanced in April 2026 through the inclusion of cannulas in shipments, packaged in 10-pack cartons for direct distribution to U.S. eye care professionals.

The company has reported treating over 100,000 patients with LACRIFILL in under two years post-clearance, an adoption signal it actively promotes at specialty ophthalmology conferences including ASCRS 2026 in Washington D.C. Its go-to-market is an enterprise field sales motion targeting ophthalmologists, with quote-based pricing that is not publicly disclosed and a revenue model that functions as a one-time product sale per treatment. Leadership comprises Anders Lofgren (Founder, Managing Director & Vice President) and Jean-Michel Quinot (President). The firm operates as a privately held company with no disclosed institutional ownership, funding rounds, or M&A activity in the available record.

Name

Nordic Pharma

Legal name

Nordic Pharma, Inc.

Website

https://nordicpharmagroup.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Nordic Pharma is the U.S. arm of privately held Nordic Group, commercializing LACRIFILL Canalicular Gel — an FDA-cleared interventional dry eye therapy sold directly to ophthalmologists via enterprise field sales. The single-SKU product has treated over 100,000 U.S. patients since its May 2024 launch.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industries

Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants) (HLAHAJAL), Eye, Ear & Nasal Care (HLAIADAF)

Keywords

• Dry eye treatment
• Ophthalmic pharmaceuticals
• Canalicular gel
• Prescription therapeutics
• Eye care products

Headquarters

HQ city

Hoofddorp

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. LACRIFILL Canalicular Gel Sales: Revenue generated from the sale of FDA-cleared LACRIFILL Canalicular Gel syringes for dry eye treatment. The product ships with cannulas in 10-pack cartons to eye care professionals in the United States.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Nordic Pharma manufactures and sells LACRIFILL Canalicular Gel, an FDA-cleared interventional ophthalmic gel delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) for the treatment of dry eye disease. The product temporarily blocks tear drainage as an alternative to traditional eye drops and is sold directly to eye care professionals and ophthalmologists in the U.S. market.

Product overview

Nordic Pharma offers a single unified product - LACRIFILL Canalicular Gel - an interventional dry eye treatment approach. The FDA-approved gel is delivered via prefilled syringes and works by temporarily blocking tear drainage to address dry eye disease affecting approximately 6.8 percent of U.S. adults. The company enhanced its offering in April 2026 by including cannulas with shipments based on physician feedback, improving provider convenience and patient experience.

Differentiator

Problem solved

Functional benefit

Brands

• LACRIFILL: LACRIFILL Canalicular Gel - FDA-cleared dry eye treatment therapy approved in May 2024 for temporarily blocking tear drainage. Product has treated over 100,000 patients in under two years.
• LACRIFILL Canalicular Gel

Products and services

• LACRIFILL Canalicular Gel FDA-cleared canalicular gel for dry eye treatment that temporarily blocks tear drainage, delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) to eye care professionals and ophthalmologists in the United States.

Quantifiable outcome

• Over 100,000 patients treated in under two years since May 2024 launch

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Alcon: A leading global ophthalmic company selling surgical, vision care, and dry eye products (e.g., Systane family). Comparable as a broad incumbent that competes across multiple ocular surface touchpoints relevant to LACRIFILL's prescriber base.
• Bausch + Lomb: A major diversified ophthalmic company with both prescription (e.g., Vyzulta, ophthalmic surgical portfolio) and consumer dry eye products (artificial tears, ointments). Comparable because it addresses the same dry eye disease category with broader resources and an established U.S. commercial footprint.
• Johnson & Johnson Vision: Operates a large ophthalmic and vision care franchise including dry eye therapeutics and ocular surface products. Comparable as a broad incumbent with deep ophthalmologist relationships and resources that materially exceed Nordic Pharma's U.S. footprint.

Direct peers

• Novartis: Sells Xiidra (lifitegrast ophthalmic solution), a major prescription dry eye therapy competing head-to-head with LACRIFILL for ophthalmologist prescriptions in the U.S. dry eye market.
• Sun Pharmaceutical Industries: Sells Cequa (cyclosporine A ophthalmic solution), a prescription dry eye therapy directly competing with LACRIFILL for ophthalmologist prescriptions and specialty pharmacy channel share in the U.S.
• AbbVie (Allergan Aesthetics): Markets Restasis (cyclosporine ophthalmic emulsion), the leading prescription dry eye therapy, and has deep relationships with U.S. ophthalmologists. Directly comparable because both compete for the same physician prescriber and dry eye patient population that LACRIFILL targets.
• Viatris (Oyster Point Pharma): Markets Tyrvaya (varenicline nasal spray) for dry eye disease and continues to develop ocular surface therapies through the Oyster Point franchise, targeting the same prescriber base and patient population as Nordic Pharma.

Emerging players

• Kala Bio: Specialty ophthalmic company developing and commercializing therapies for rare ocular surface diseases, including dry eye indications. Comparable as a smaller, focused ophthalmic player competing in adjacent ocular surface categories.
• Sight Sciences: Commercial-stage ophthalmic company focused on interventional treatments for glaucoma and dry eye (e.g., TearCare). Comparable because it pursues procedure-based, interventional approaches in the ophthalmologist's office—a similar commercial model to LACRIFILL.
• Aerie Pharmaceuticals (Alcon): Developed and commercialized ophthalmic pharmaceuticals including dry eye therapies (e.g., Rocklatan and related pipeline) before being acquired by Alcon. Comparable as a specialty ophthalmic pharma with prescription dry eye franchise overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordic Pharma